CAS
CORT icon

Coppell Advisory Solutions’s Corcept Therapeutics CORT Stock Holding History

Coppell Advisory Solutions’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-44,745
Closed -$3.14M – 68
2025
Q4 		$3.14M Buy
44,745
+4,644
+12% +$365K 0.31% 66
2025
Q3 		$3.36M Buy
40,101
+8,486
+27% +$614K 0.36% 54
2025
Q2 		$2.31M Buy
31,615
+14,305
+83% +$1.04M 0.27% 70
2025
Q1 		$1.27M Buy
17,310
+14,590
+536% +$888K 0.18% 128
2024
Q4 		$138K Buy
2,720
+1,586
+140% +$83.1K 0.02% 353
2024
Q3 		$49.8K Buy
1,134
+1,130
+28,250% +$40.2K 0.01% 555
2024
Q2 		$130 Buy
+4
New +$110 ﹤0.01% 1689
2023
Q4 		$1.04K Buy
+32
New +$879 ﹤0.01% 1408

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Coppell Advisory Solutions's CORT Position: Q1 2026 in Review

Coppell Advisory Solutions sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 44,745 shares — an estimated $3.14M sold.

Coppell Advisory Solutions first reported a position in CORT in Q4 2023 and held it in 8 quarters. The position peaked at $3.36M in Q3 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Coppell Advisory Solutions reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Coppell Advisory Solutions sold 44,745 Corcept Therapeutics shares in Q1 2026, an estimated $3.14M.
  • Coppell Advisory Solutions first reported a position in Corcept Therapeutics in Q4 2023 and held it in 8 quarters.
  • Coppell Advisory Solutions's Corcept Therapeutics position peaked at $3.36M in Q3 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Coppell Advisory Solutions's 13F filing for Q1 2026, filed 15 May 2026.